These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35725444)

  • 1. Mass cytometry reveals immune atlas of urothelial carcinoma.
    Zhang Q; Zhang W; Lin T; Lu W; He X; Ding Y; Chen W; Diao W; Ding M; Shen P; Guo H
    BMC Cancer; 2022 Jun; 22(1):677. PubMed ID: 35725444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.
    Eich ML; Chaux A; Guner G; Taheri D; Mendoza Rodriguez MA; Rodriguez Peña MDC; Baras AS; Hahn NM; Drake C; Sharma R; Bivalacqua TJ; Rezaei K; Netto GJ
    Hum Pathol; 2019 Jul; 89():24-32. PubMed ID: 31026471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
    Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
    Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: durable complete response to pembrolizumab plus lenvatinib in a metastatic upper tract urothelial carcinoma patient with high tumor mutational burden and an immune-active tumor microenvironment.
    Jin J; Li J; Peng C; Chen J; Xu G; Pan S
    Anticancer Drugs; 2023 Jul; 34(6):797-802. PubMed ID: 36729952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MLKL and other necroptosis-related genes promote the tumor immune cell infiltration, guiding for the administration of immunotherapy in bladder urothelial carcinoma.
    Zhong B; Wang Y; Liao Y; Liang J; Wang K; Zhou D; Zhao Y; Jiang N
    Apoptosis; 2023 Jun; 28(5-6):892-911. PubMed ID: 37000317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
    Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
    Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell atlases link macrophages and CD8
    Liang Y; Tan Y; Guan B; Guo B; Xia M; Li J; Shi Y; Yu Z; Zhang Q; Liu D; Yang X; Hao J; Gong Y; Shakeel M; Zhou L; Ci W; Li X
    Theranostics; 2022; 12(18):7745-7759. PubMed ID: 36451860
    [No Abstract]   [Full Text] [Related]  

  • 9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes.
    Li H; Zhang Q; Shuman L; Kaag M; Raman JD; Merrill S; DeGraff DJ; Warrick JI; Chen G
    Sci Rep; 2020 Jan; 10(1):1439. PubMed ID: 31996725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.
    Kates M; Nirschl TR; Baras AS; Sopko NA; Hahn NM; Su X; Zhang J; Kochel CM; Choi W; McConkey DJ; Drake CG; Bivalacqua TJ
    Eur Urol Oncol; 2021 Feb; 4(1):117-120. PubMed ID: 31411999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile.
    Peng M
    Front Immunol; 2022; 13():970885. PubMed ID: 36003383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance.
    Jing W; Wang G; Cui Z; Xiong G; Jiang X; Li Y; Li W; Han B; Chen S; Shi B
    Cancer Res; 2022 Jan; 82(1):114-129. PubMed ID: 34753771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma.
    Podojil JR; Glaser AP; Baker D; Courtois ET; Fantini D; Yu Y; Eaton V; Sivajothi S; Chiang M; Das A; McLaughlin KA; Robson P; Miller SD; Meeks JJ
    Oncoimmunology; 2020; 9(1):1744897. PubMed ID: 32363111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.
    Wang L; Smith BA; Balanis NG; Tsai BL; Nguyen K; Cheng MW; Obusan MB; Esedebe FN; Patel SJ; Zhang H; Clark PM; Sisk AE; Said JW; Huang J; Graeber TG; Witte ON; Chin AI; Park JW
    Proc Natl Acad Sci U S A; 2020 Jan; 117(1):563-572. PubMed ID: 31871155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
    Park JC; Hahn NM
    Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
    Yan S; Zeng H; Jin K; Shao F; Liu Z; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Xu J
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35523436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
    Davick JJ; Frierson HF; Smolkin M; Gru AA
    Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of an IDO1-based immune classifier for survival prediction of upper tract urothelial carcinoma.
    Zhong W; Yang M; Cheng S; Hou W; Wang B; Chen J; Yu H; Ouyang Y; Wang X; Ou Z; Xu P; Li X; Zhou L; Huang J; Wang C; Lin T
    Cancer Sci; 2022 Mar; 113(3):852-863. PubMed ID: 34962030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avelumab for the treatment of urothelial cancer.
    Rodriguez-Vida A; Bellmunt J
    Expert Rev Anticancer Ther; 2018 May; 18(5):421-429. PubMed ID: 29540084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.